Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) traded up 3.7% on Wednesday . The company traded as high as $21.40 and last traded at $21.31, with a volume of 218,045 shares. The stock had previously closed at $20.55.

A number of equities research analysts have recently weighed in on the stock. Jefferies Group restated a “buy” rating and issued a $23.00 price objective (up from $19.00) on shares of Supernus Pharmaceuticals in a report on Thursday, May 12th. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Wednesday. Piper Jaffray Cos. restated an “overweight” rating and issued a $24.00 price objective on shares of Supernus Pharmaceuticals in a report on Saturday, April 2nd. TheStreet upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 29th. Finally, Northland Securities reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, March 11th. Five research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $23.00.

The company has a 50-day moving average of $19.17 and a 200 day moving average of $15.52. The stock has a market cap of $1.02 billion and a P/E ratio of 61.18.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by $0.01. During the same period in the prior year, the business posted $0.02 earnings per share. The business had revenue of $43 million for the quarter, compared to analyst estimates of $45.33 million. Supernus Pharmaceuticals’s quarterly revenue was up 53.0% on a year-over-year basis. On average, analysts anticipate that Supernus Pharmaceuticals Inc. will post $0.62 EPS for the current year.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 30,762 shares of the stock in a transaction that occurred on Monday, April 11th. The shares were sold at an average price of $16.49, for a total transaction of $507,265.38. Following the completion of the sale, the vice president now directly owns 57,306 shares of the company’s stock, valued at approximately $944,975.94. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Other large investors recently made changes to their positions in the company. Kornitzer Capital Management Inc. KS raised its stake in shares of Supernus Pharmaceuticals by 49.5% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 1,245,170 shares of the specialty pharmaceutical company’s stock worth $16,735,000 after buying an additional 412,280 shares during the period. Russell Frank Co raised its stake in shares of Supernus Pharmaceuticals by 109.0% in the fourth quarter. Russell Frank Co now owns 648,277 shares of the specialty pharmaceutical company’s stock worth $8,871,000 after buying an additional 338,145 shares during the period. California State Teachers Retirement System raised its stake in shares of Supernus Pharmaceuticals by 579.2% in the fourth quarter. California State Teachers Retirement System now owns 424,712 shares of the specialty pharmaceutical company’s stock worth $5,708,000 after buying an additional 362,178 shares during the period. Strs Ohio raised its stake in shares of Supernus Pharmaceuticals by 58.1% in the fourth quarter. Strs Ohio now owns 283,640 shares of the specialty pharmaceutical company’s stock worth $3,812,000 after buying an additional 104,240 shares during the period. Finally, EAM Investors LLC raised its stake in shares of Supernus Pharmaceuticals by 10.0% in the fourth quarter. EAM Investors LLC now owns 236,833 shares of the specialty pharmaceutical company’s stock worth $3,183,000 after buying an additional 21,568 shares during the period.

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.